# Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma

> **NCT04566887** · PHASE2 · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 105 (estimated)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Acalabrutinib
- **DRUG:** R-CHOP chemotherapy

## Key facts

- **NCT ID:** NCT04566887
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-03-01
- **Primary completion:** 2023-09-30
- **Final completion:** 2032-04-30
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2025-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04566887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04566887, "Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04566887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*